FACTORS ASSOCIATED WITH VARIABILITY IN IL-6 LEVELS IN PATIENTS WITH COVID-19

Authors

DOI:

https://doi.org/10.11603/1681-2727.2023.2.14097

Keywords:

COVID-19, interleukin-6, comorbidity, age characteristics

Abstract

SUMMARY. An increase in the systemic level of IL-6 in patients with COVID-19 is considered as a relevant parameter for predicting the most severe course of the disease and the need for intensive therapy. We conducted a study of the level of interleukin-6 in 77 patients with coronavirus disease aged from 29 to 87 years (mean age 59.3±12.4 years), among whom there were men – 43 (55.8 %), women – 34 (44.2 %). The examination was carried out the next day after hospitalization. On average, the period from the onset of the disease was (9.2±3.5) days. According to the results of the study, it was established that the average level of IL-6 among patients with COVID-19 significantly exceeded the similar indicator in relatively healthy individuals: Me – 5.30 (3.57; 11.32) pg/l against 2.68 (2,22; 2.97) (p<0.001).

Analysis of IL-6 content depending on demographic, clinical and general laboratory characteristics showed that its increase in blood serum correlates with age (rs=0.251, p=0.030), and the highest average level of this cytokine was observed in the age group of 70–79 years (rs=0.381, p=0.001). among the clinical characteristics, the correlation of the level of IL-6 with the severe course of the disease was determined (rs=0.381, p=0.001), which corresponds to the role of this cytokine as a possible marker of the progression of the severe course of the disease. Accordingly, there is also a tendency to link the fatal outcome of the disease with an increase in the level of IL-6 (rs=0.210, p=0.071), which may have a reliable result with a larger number of observations. Among the general laboratory indicators, a direct correlation was observed between the level of IL-6 and the ESR value (rs=0.271, p=0.019), the number of bands (rs=0.301, p=0.009), residual nitrogen (rs=0.231, p=0.047), the content of CRP (rs=0.241, p=0.037), which, like IL-6, is an important marker of the acute phase of inflammation, and high levels of this protein in the early stage of coronavirus disease are positively correlated with the degree of lung damage and the severity of the disease. Thus, as a result of the conducted study, it was established that the increase in the level of interleukin-6, which is observed in patients with COVID-19 is correlated with the severity of the disease and may also be related to age (especially the age group of 70–79 years) and a number of concomitant pathology and clinical conditions, among which coronary heart disease, obesity, fever, increased BP (systolic), decreased saturation are especially important. Higher levels of interleukin-6 are observed with an increase in the content of C-reactive protein, residual nitrogen, ESR, and the number of bands.

Author Biographies

K. Yu. Lytvyn, Dnipro State Medical University

MD, Professor, Head of the Department of Infectious Diseases, Dnipro State Medical University

O. O. Bilokon, Dnipro State Medical University

assistant, graduate student of the Department of Infectious Diseases, Dnipro State Medical University

References

McGonagle, D., Sharif, K., O’Regan, A., & Bridgewood, C. (2020). The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmunity Reviews, 19 (6), 102537. Available from https://doi.org/10.1016/j.autrev.2020.102537 DOI: https://doi.org/10.1016/j.autrev.2020.102537

Wang, Y., & Perlman, S. (2022). COVID-19: inflammatory profile. Annual review of medicine, 73, 65-80. Available from: https://doi.org/10.1146/annurev-med-042220-012417 DOI: https://doi.org/10.1146/annurev-med-042220-012417

Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., ... & Wang, F. S. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine, 8(4), 420-422. Available from: https://doi.org/10.1016/S2213-2600(20)30076-X DOI: https://doi.org/10.1016/S2213-2600(20)30076-X

Vatansever, H. S., & Becer, E. (2020). Relationship between IL-6 and COVID-19: to be considered during treatment. Future Virology, 15(12), 817-822. Available from: https://doi.org/10.2217/fvl-2020-0168 DOI: https://doi.org/10.2217/fvl-2020-0168

Fattori, E., Cappelletti, M., Costa, P., Sellitto, C., Cantoni, L., Carelli, M., ... & Poli, V. (1994). Defective inflammatory response in interleukin 6-deficient mice. The Journal of Experimental Medicine, 180 (4), 1243-1250. https://doi.org/10.1084/jem.180.4.1243. DOI: https://doi.org/10.1084/jem.180.4.1243

Otsuka, R., & Seino, K.I. (2020). Macrophage activation syndrome and COVID-19. Inflammation and regeneration, 40, 1-6. Available from: https://doi.org/10.1186/s41232-020-00131-w DOI: https://doi.org/10.1186/s41232-020-00131-w

Stüber, F., Wrigge, H., Schroeder, S., Wetegrove, S., Zinserling, J., Hoeft, A., & Putensen, C. (2002). Kinetic and reversibility of mechanical ventilation-associated pulmonary and systemic inflammatory response in patients with acute lung injury. Intensive Care Medicine, 28, 834-841. https://doi.org/10.1007/s00134-002-1321-7 DOI: https://doi.org/10.1007/s00134-002-1321-7

Parsons, P. E., Eisner, M. D., Thompson, B. T., Matthay, M. A., Ancukiewicz, M., Bernard, G. R., ... & NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network. (2005). Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Critical Care Medicine, 33 (1), 1-6. https://doi.org/10.1097/01.ccm.0000149854.61192.dc DOI: https://doi.org/10.1097/01.CCM.0000149854.61192.DC

McElvaney, O. J., Curley, G. F., Rose-John, S., & McElvaney, N. G. (2021). Interleukin-6: obstacles to targeting a complex cytokine in critical illness. The Lancet Respiratory Medicine, 9(6), 643-654. https://doi.org/10.1016/S2213-2600(21)00103-X DOI: https://doi.org/10.1016/S2213-2600(21)00103-X

Halim, C., Mirza, A. F., & Sari, M. I. (2022). The association between TNF-α, IL-6, and vitamin D levels and COVID-19 severity and mortality: a systematic review and meta-analysis. Pathogens, 11 (2), 195. Available from: https://doi.org/10.3390/pathogens11020195 DOI: https://doi.org/10.3390/pathogens11020195

Tian, W., Jiang, W., Yao, J., Nicholson, C. J., Li, R. H., Sigurslid, H. H., ... & Malhotra, R. (2020). Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. Journal of medical virology, 92(10), 1875-1883. Available from: https://doi.org/10.1002/jmv.26050 DOI: https://doi.org/10.1002/jmv.26050

Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K., Desai, P., ... & Altaf, M. (2020). Comorbidity and its impact on patients with COVID-19. SN comprehensive clinical medicine, 2, 1069-1076. Available from: https://doi.org/10.1007/s42399-020-00363-4

Bilokon, O. O., & Lytvyn, K. Yu. (2023). Analysis of clinical and laboratory characteristics of COVID-19 in elderly patients. Bilokon, O. O., & Lytvyn, K. Yu. (2023). Analysis of clinical and laboratory characteristics of COVID-19 in elderly patients. Infectious Diseases, 3, 12–17. https://doi.org/10.11603/1681-2727.2022.3.13472 [in Ukrainian] DOI: https://doi.org/10.11603/1681-2727.2022.3.13472

Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K., Desai, P., ... & Altaf, M. (2020). Comorbidity and its impact on patients with COVID-19. SN Comprehensive Clinical Medicine, 2, 1069-1076. Available from: https://doi.org/10.1007/s42399-020-00363-4 DOI: https://doi.org/10.1007/s42399-020-00363-4

Meftahi, G. H., Jangravi, Z., Sahraei, H., & Bahari, Z. (2020). The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging”. Inflammation Research, 69, 825-839. https://doi.org/10.1007/s00011-020-01372-8 DOI: https://doi.org/10.1007/s00011-020-01372-8

Gubernatorova, E. O., Gorshkova, E. A., Polinova, A. I., & Drutskaya, M. S. (2020). IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine & Growth Factor Reviews, 53, 13-24. https://doi.org/10.1016/j.cytogfr.2020.05.009

Antomonov, M. Yu. (2018). Mathematical processing and analysis of medical and biological data. 2nd edition. Kyiv: MIT Medinform [in Ukrainian].

Gubernatorova, E. O., Gorshkova, E. A., Polinova, A. I., & Drutskaya, M. S. (2020). IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine & Growth Faactor Reviews, 53, 13-24. https://doi.org/10.1016/j.cytogfr.2020.05.009 DOI: https://doi.org/10.1016/j.cytogfr.2020.05.009

Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. Nature, 444 (7121), 860-867. https://doi.org/10.1038/nature05485 DOI: https://doi.org/10.1038/nature05485

Chae, C. U., Lee, R. T., Rifai, N., & Ridker, P. M. (2001). Blood pressure and inflammation in apparently healthy men. Hypertension, 38 (3), 399-403. https://doi.org/10.1161/01.hyp.38.3.399 DOI: https://doi.org/10.1161/01.HYP.38.3.399

Akbari, M., & Hassan-Zadeh, V. (2018). IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology, 26, 685-698. https://doi.org/10.1007/s10787-018-0458-0 DOI: https://doi.org/10.1007/s10787-018-0458-0

Wang, L. (2020). C-reactive protein levels in the early stage of COVID-19. Medecine et maladies infectieuses, 50 (4), 332-334. https://doi.org/10.1016/j.medmal.2020.03.007 DOI: https://doi.org/10.1016/j.medmal.2020.03.007

Lu, L., Zhang, H., Dauphars, D. J., & He, Y. W. (2021). A potential role of interleukin 10 in COVID-19 pathogenesis. Trends in Immunology, 42 (1), 3-5. https://doi.org/10.1016/j.it.2020.10.012 DOI: https://doi.org/10.1016/j.it.2020.10.012

Published

2023-05-30

How to Cite

Lytvyn, K. Y., & Bilokon, O. O. (2023). FACTORS ASSOCIATED WITH VARIABILITY IN IL-6 LEVELS IN PATIENTS WITH COVID-19. Infectious Diseases – Infektsiyni Khvoroby, (2), 9–14. https://doi.org/10.11603/1681-2727.2023.2.14097

Issue

Section

Original investigations